Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
Lissoni
P
P
Barni
S
S
Di Felice
G
G
Majorca
F
F
Fumagalli
L
L
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D018664:Interleukin-12 / Q000097:blood*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000378:metabolism*; D007680:Kidney Neoplasms / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D019798:Neopterin / Q000097:blood*; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012995:Solubility
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D018664:Interleukin-12; D019798:Neopterin